Veracyte (VCYT) announced that more than 15 studies focused on the Decipher portfolio will be presented at the 2026 American Urological Association, AUA, Annual Meeting, taking place May 15-18 in Washington, D.C. The data showcases the growing impact of the Decipher Bladder and Prostate tests to inform more personalized patient care. The studies provide insights into molecular subtypes associated with patient outcomes in bladder cancer and feature national-scale real-world data analyses in prostate cancer that demonstrate how Decipher Prostate informs treatment decisions. Additional real-world data from the Decipher Genomics Research for Intelligent Discovery, GRID, research tool continues to fuel the flywheel of evidence in urologic cancers through ongoing research studies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VCYT:
- Veracyte price target lowered to $40 from $43 at Canaccord
- Veracyte initiated with a Buy at Jefferies
- Veracyte: Leveraging TrueMRD and Decipher Bladder to Capture a $200M Minimal Residual Disease Opportunity
- Veracyte price target lowered to $45 from $50 at Guggenheim
- Veracyte Appoints Kevin Haas as Chief Technology Leader